Jan 09, 2020 / 09:00PM GMT
Terence C. Flynn - Goldman Sachs Group Inc., Research Division - MD
Well, thanks so much, Bob and Peter, for joining us. I'm Terence Flynn, the biopharma analyst here at Goldman Sachs. And this afternoon to close out the CEO conference, we're very pleased to have Amgen joining us via video conference. Thank you to Bob and Peter. Bob Bradway is Chairman and CEO; Peter Griffith is the new CFO of the company, but thank you both for joining us today.
First, I'm going to turn it over to Bob to make some opening remarks to kick it off, and then we'll go through a number of questions. But thanks, again, guys.
Robert A. Bradway - Amgen Inc. - Chairman, CEO & President
Well, thanks for having us, Terence. I hope your event is going well. I'll just point out that Arvind is also here with us in the room. So we're delighted to be here and to be included in your conference.
I'll be brief, because I know it's getting late in the day for you on your end. But let me just start by saying that we're feeling confident about the outlook for 2020. And we are
Amgen Inc at Goldman Sachs Healthcare CEOs Unscripted: A View from the Top Transcript
Jan 10, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers